US Pharma MarketingExclusive: Spot Bio launches with $40M to study mRNA therapy for muscular dystrophy
Spot Biosystems emerges from stealth with $40M raised, reporting early human data showing dystrophin restoration in two children with Duchenne muscular dystrophy. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push…
A startup with operations in California and China has quietly begun tests of a genetic medicine that could restore dystrophin, the vital muscle protein that is broken or missing in people born with Duchenne muscular ...
Source: Endpoints News